News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 12, 2024

ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Author(s)Kirollos S. Hanna, PharmD, BCPS, BCOP, Hope Rugo, MD, Joyce O’Shaughnessy, MD

A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.

Episodes in this series

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 1 Factors Influencing Decisions to Prescribe a CDK4/6 Inhibitor in Early Breast Cancer

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 2 Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial

EP. 3 Outcomes from NATALEE and MonarchE

EP. 3 Outcomes from NATALEE and MonarchE

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

EP. 4 Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment

A panel of 4 experts on breast cancer

EP. 5 Primary Differences in the Toxicity Profiles of Abemaciclib and Ribociclib

A panel of 4 experts on breast cancer

EP. 6 Dr Dempsey Shares How the Type of Endocrine Therapy Can Impact Toxicities Seen in Her Patients

A panel of 4 experts on breast cancer

EP. 7 Hope Rugo, MD Shares Her Management Strategy for GI Toxicities with Abema

A panel of 4 experts on breast cancer

EP. 8 Dr. O’Shaughnessy Shares Her Management Strategy for Hematologic Toxicities with Ribociclib

A panel of 4 experts on breast cancer

EP. 9 Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 10 How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

A panel of 4 experts on breast cancer

EP. 11 Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors

A panel of 4 experts on breast cancer

EP. 12 Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies

A panel of 4 experts on breast cancer

EP. 13 ASCO 2024 Review and Needed Future Research in CDK4/6 inhibitors Early Breast Cancer

Video content above is prompted by the following question(s):

What future research is needed to further support decision-making when using CDK4/6 inhibitors for early breast cancer?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Multidisciplinary Geriatric Oncology Improves Breast Cancer Care: Enrique Soto Perez de Celis, MD

BySabrina McCrear,Enrique Soto Perez de Celis, MD, PhD

July 29th 2026

Enrique Soto Perez de Celis

Older Adult Priorities Should Shape Breast Cancer Trial Design: Enrique Soto Perez de Celis, MD, PhD

BySabrina McCrear,Enrique Soto Perez de Celis, MD, PhD

July 28th 2026

Denise Yardley, MD | Image Credit: Sarah Cannon Research Institute

Breast Cancer De-Escalation Now Rests on Molecular Profiling: Denise Yardley, MD

ByElla Hohmann, MS,Denise Yardley, MD

July 28th 2026

Denver Skyline | Image Credit: © f11photo-stock.adobe.com

Precision Therapies Are Advancing Fast, and Care Delivery Has to Catch Up

BySabrina McCrear

July 28th 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

5 FDA Firsts From June

ByBrooke McCormick

July 24th 2026

Trending on AJMC

FDA Approves Novel Iberdomide Regimen in RRMM

Iberdomide Approval Elevates MRD’s Role in Myeloma: Prerna Mewawalla, MD

AI Model Outperforms Apnea-Hypopnea Index in Predicting Sleep Apnea Mortality Risk

IL-17 Signaling Bridges Psoriasis and Cardiometabolic Risk, Review Finds

Topical Delgocitinib Rivals Dupilumab for Hand Eczema, but Adherence Is Key